# Tigermed

Major Chinese CROs and consulting groups (like Tigermed) specialize in bridging the gap between China's National Medical Products Administration (NMPA) and the US FDA for cross-border drug development.

Source: https://en.bioecon.ru/companies/tigermed/
Updated: 2026-06-24

- Country: China
- Ticker: SZSE:300347

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Headcount | 11,984 global employees as of June 30, 2026 | https://www.prnewswire.com/news-releases/tigermed-announces-2026-interim-results-302862700.html, https://www.tigermedgrp.com/en/our-company, https://www.tigermedgrp.com/files/2ac939093da780752dbc8ad73aa5fdd4.pdf |
| Revenue | RMB 3,707.6 million for the first half of 2026 | https://www.prnewswire.com/news-releases/tigermed-announces-2026-interim-results-302862700.html |
| Production site | 25 laboratory facilities across China, the U.S., and Europe, and a 4,300 sqm CDMO GMP manufacturing facility in Exton, U.S. as of June 30, 2026 | https://tigermedgrp.com/files/2ac939093da780752dbc8ad73aa5fdd4.pdf, https://tigermedgrp.com/files/51167a318f1b3e1d5756e3f590d34911.pdf, https://www.prnewswire.com/news-releases/tigermed-announces-2026-interim-results-302862700.html, https://www.tigermedgrp.com/en/media-resources/press-releases/197, https://www.tigermedgrp.com/files/2ac939093da780752dbc8ad73aa5fdd4.pdf |
| Capacity | 6 co-established clinical sites with a total of 620 research beds as of June 30, 2026 | https://www.prnewswire.com/news-releases/tigermed-announces-2026-interim-results-302862700.html, https://www.tigermedgrp.com/en/media-resources/press-releases/197 |
| Certification | Taya AI platform obtained ISO 20000 and ISO 27001 certifications; laboratories passed CAP accreditation | https://tigermedgrp.com/files/51167a318f1b3e1d5756e3f590d34911.pdf, https://www.tigermedgrp.com/files/51167a318f1b3e1d5756e3f590d34911.pdf |
| Regulatory approval | Assisted in 49 Class I new drug and 5 innovative medical device approvals in China in 2025 | https://tigermedgrp.com/files/51167a318f1b3e1d5756e3f590d34911.pdf, https://www.tigermedgrp.com/files/2ac939093da780752dbc8ad73aa5fdd4.pdf, https://www.tigermedgrp.com/files/51167a318f1b3e1d5756e3f590d34911.pdf |
| Partnership | Strategic cooperation agreements with Hisun Pharmaceutical, Insilico Medicine, 3SBio, and a leading European multinational pharmaceutical company in H1 2026 | https://www.prnewswire.com/news-releases/tigermed-announces-2026-interim-results-302862700.html |

Independent sources: prnewswire.com

## Technologies

- [CMC regulatory consulting (BLA/MAA)](https://en.bioecon.ru/technology/cmc-regulatory-consulting/)
- [Multi-jurisdictional bio-compliance (FDA+EMA+NMPA+PMDA)](https://en.bioecon.ru/technology/multi-jurisdictional-bio-compliance/)
- [Named-patient programs & compassionate use](https://en.bioecon.ru/technology/named-patient-compassionate-use/)